MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 527755 | Name: EM20-25

Description:

WARNING: This product is for research use only, not for human or veterinary use.

EM20-25 is a novel BCL-2 inhibitor, neutralizing the antiapoptotic activity of overexpressed BCL-2 toward staurosporine and sensitizing BCL-2-expressing cells from leukemic patients to the killing effects of staurosporine, chlorambucil, and fludarabine.

Chemical Structure

EM20-25
EM20-25
CAS#141266-44-6

Theoretical Analysis

MedKoo Cat#: 527755

Name: EM20-25

CAS#: 141266-44-6

Chemical Formula: C15H9ClN4O6

Exact Mass: 376.0211

Molecular Weight: 376.71

Elemental Analysis: C, 47.83; H, 2.41; Cl, 9.41; N, 14.87; O, 25.48

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
EM2025; EM20 25; EM20-25
IUPAC/Chemical Name
5-(6-Chloro-2,4-dioxo-1,3,4,10-tetrahydro-2H-9-oxa-1,3-diaza-anthracen-10-yl)-pyrimidine-2,4,6-trione
InChi Key
GGEVZGGAQHNWQN-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H9ClN4O6/c16-4-1-2-6-5(3-4)7(8-10(21)17-14(24)18-11(8)22)9-12(23)19-15(25)20-13(9)26-6/h1-3,7-8H,(H2,19,20,23,25)(H2,17,18,21,22,24)
SMILES Code
O=C1NC(C(C2C3=C(NC(NC3=O)=O)OC4=C2C=C(Cl)C=C4)C(N1)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 376.71 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Vasaikar SV, Ghosh S, Narain P, Basu A, Gomes J. HSP70 mediates survival in apoptotic cells-Boolean network prediction and experimental validation. Front Cell Neurosci. 2015 Aug 25;9:319. doi: 10.3389/fncel.2015.00319. eCollection 2015. PubMed PMID: 26379495; PubMed Central PMCID: PMC4548197. 2: Ciscato F, Sciacovelli M, Villano G, Turato C, Bernardi P, Rasola A, Pontisso P. SERPINB3 protects from oxidative damage by chemotherapeutics through inhibition of mitochondrial respiratory complex I. Oncotarget. 2014 May 15;5(9):2418-27. PubMed PMID: 24810714; PubMed Central PMCID: PMC4058015. 3: Buron N, Porceddu M, Brabant M, Desgué D, Racoeur C, Lassalle M, Péchoux C, Rustin P, Jacotot E, Borgne-Sanchez A. Use of human cancer cell lines mitochondria to explore the mechanisms of BH3 peptides and ABT-737-induced mitochondrial membrane permeabilization. PLoS One. 2010 Mar 31;5(3):e9924. doi: 10.1371/journal.pone.0009924. PubMed PMID: 20360986; PubMed Central PMCID: PMC2847598. 4: Rasola A, Sciacovelli M, Chiara F, Pantic B, Brusilow WS, Bernardi P. Activation of mitochondrial ERK protects cancer cells from death through inhibition of the permeability transition. Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):726-31. doi: 10.1073/pnas.0912742107. Epub 2009 Dec 22. PubMed PMID: 20080742; PubMed Central PMCID: PMC2818893. 5: Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer MJ, Cohen GM. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ. 2009 Jul;16(7):1030-9. doi: 10.1038/cdd.2009.48. Epub 2009 Apr 24. PubMed PMID: 19390557. 6: Tumilasci VF, Olière S, Nguyên TL, Shamy A, Bell J, Hiscott J. Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis. J Virol. 2008 Sep;82(17):8487-99. doi: 10.1128/JVI.00851-08. Epub 2008 Jun 25. PubMed PMID: 18579592; PubMed Central PMCID: PMC2519628. 7: Milanesi E, Costantini P, Gambalunga A, Colonna R, Petronilli V, Cabrelle A, Semenzato G, Cesura AM, Pinard E, Bernardi P. The mitochondrial effects of small organic ligands of BCL-2: sensitization of BCL-2-overexpressing cells to apoptosis by a pyrimidine-2,4,6-trione derivative. J Biol Chem. 2006 Apr 14;281(15):10066-72. Epub 2006 Feb 14. PubMed PMID: 16481323.